Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
Stock Information for Achieve Life Sciences Inc.
Loading
Please wait while we load your information from QuoteMedia.